Precision BioSciences to Present at Hep-DART 2023
30 Novembro 2023 - 9:00AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene
editing company utilizing its novel proprietary ARCUS® platform to
develop in vivo gene editing therapies for sophisticated gene
edits, including gene insertion, excision, and elimination, today
announced that the company will present at Hep-DART 2023 in an
industry session and host a poster presentation on December 5,
2023, in Los Cabos, Mexico.
Presentation Details:
Title: Precision Biosciences' PBGENE-HBV Program: A
potentially curative strategy to eliminate cccDNA and inactivate
integrated HBV DNA through gene editing Presenters: Jeff
Smith, Co-Founder and Chief Research Officer, Precision
BioSciences; Emily Harrison, HBV Research Lead, Precision
BioSciences Date and Time: Tuesday, December 5, 2023, 11:55
AM – 12:10 PM MST Location: Hacienda Del Mar Main
Presentation Venue
Title: “Preclinical efficacy and safety of ARCUS-POL
nucleases for chronic hepatitis B: a potentially curative strategy”
Poster Number: Poster #42 Presenter: Emily Harrison,
HBV Research Lead, Precision BioSciences Date and Time:
Tuesday, December 5, 2023, 2:30 PM – 4:00 PM MST Location:
Hacienda Del Mar Poster Session Venue
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company
dedicated to improving life (DTIL) with its novel and proprietary
ARCUS® genome editing platform that differs from other technologies
in the way it cuts, its smaller size, and its simpler structure.
Key capabilities and differentiating characteristics may enable
ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, the Company’s pipeline is comprised of in
vivo gene editing candidates designed to deliver lasting cures for
the broadest range of genetic and infectious diseases where no
adequate treatments exist. For more information about Precision
BioSciences, please visit www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231130882274/en/
Investor and Media Contact: Mei Burris Senior Director of
Finance and Corporate Controller
Mei.Burris@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
